• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体功能减退症患者的血管性死亡率会增加吗?

Is vascular mortality increased in hypopituitarism?

作者信息

Erfurth E M, Bülow B, Hagmar L E

机构信息

Department of Internal Medicine, Division of Endocrinology, University Hospital, SE-221 85 Lund, Sweden.

出版信息

Pituitary. 2000 Oct;3(2):77-81. doi: 10.1023/a:1009901707125.

DOI:10.1023/a:1009901707125
PMID:11141699
Abstract

Hitherto four relevant cohort studies have been published on the life expectancy of patients with hypopituitarism, two from the UK and two from Sweden. In all four studies patients with acromegaly or Cushing's disease were excluded, and patients with GH replacement were not included. A crude meta-analysis, not considering differences in validity of the study designs, gives an overall Relative Risk (RR) of 1.47, with a relatively small 95% confidence interval of 1.27-1.70. The aim of this critical review was to assess whether lacking validity in the design of one or several of these studies indicates that the true RR might be higher or lower than indicated by meta-analyses. A high frequency of cranial irradiation in one of the Swedish cohorts may explain part of the very high observed RR for cerebrovascular mortality, but there remained a 40% risk increase for cardiac diseases that cannot be explained by irradiation. Some other validity problems, especially seen in the UK studies, will result in under-estimation of the true RR, but for others the direction of bias is uncertain due to lacking information in the original publications. According to our view, it is more probable that the observed overall 50% risk increase for vascular mortality is an under-estimation than an over-estimation of the true RR. This analysis is of a qualitative nature, and it is not possible to quantify to what extent the lacking validity may have affected the RR.

摘要

迄今为止,已发表了四项关于垂体功能减退症患者预期寿命的相关队列研究,两项来自英国,两项来自瑞典。在所有四项研究中,肢端肥大症或库欣病患者被排除在外,接受生长激素替代治疗的患者未被纳入。一项未考虑研究设计有效性差异的粗略荟萃分析得出的总体相对风险(RR)为1.47,95%置信区间相对较小,为1.27 - 1.70。这篇批判性综述的目的是评估这些研究中一项或多项研究设计缺乏有效性是否表明真实的RR可能高于或低于荟萃分析所示。瑞典的一个队列中颅脑照射频率较高,这可能部分解释了观察到的脑血管死亡率RR非常高的原因,但心脏病风险仍有40%的增加无法用照射来解释。其他一些有效性问题,特别是在英国的研究中发现的,将导致对真实RR的低估,但对于其他问题,由于原始出版物中缺乏信息,偏差方向尚不确定。根据我们的观点,观察到的血管死亡率总体风险增加50%更有可能是对真实RR的低估而非高估。这种分析是定性的,无法量化缺乏有效性可能在多大程度上影响了RR。

相似文献

1
Is vascular mortality increased in hypopituitarism?垂体功能减退症患者的血管性死亡率会增加吗?
Pituitary. 2000 Oct;3(2):77-81. doi: 10.1023/a:1009901707125.
2
Life expectancy following surgery for pituitary tumours.垂体瘤手术后的预期寿命。
Clin Endocrinol (Oxf). 1999 Mar;50(3):315-9. doi: 10.1046/j.1365-2265.1999.00650.x.
3
The effect of hypopituitarism on life expectancy.垂体功能减退对预期寿命的影响。
J Clin Endocrinol Metab. 1996 Mar;81(3):1169-72. doi: 10.1210/jcem.81.3.8772595.
4
Increased cerebrovascular mortality in patients with hypopituitarism.垂体功能减退患者脑血管死亡率增加。
Clin Endocrinol (Oxf). 1997 Jan;46(1):75-81. doi: 10.1046/j.1365-2265.1997.d01-1749.x.
5
Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.全国性研究显示肢端肥大症患者的死亡率降低和治疗模式的改变。
Eur J Endocrinol. 2018 May;178(5):459-469. doi: 10.1530/EJE-18-0015. Epub 2018 Feb 26.
6
Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies.成人垂体功能减退相关的超额死亡率:观察性研究的荟萃分析。
J Clin Endocrinol Metab. 2015 Apr;100(4):1405-11. doi: 10.1210/jc.2014-3787. Epub 2015 Feb 6.
7
Overall and cause-specific mortality in GH-deficient adults on GH replacement.生长激素缺乏症成人接受生长激素替代治疗后的总体死亡率和死因特异性死亡率。
Eur J Endocrinol. 2012 Jun;166(6):1069-77. doi: 10.1530/EJE-11-1028. Epub 2012 Mar 28.
8
Mortality, cardiovascular events and risk factors in hypopituitarism.垂体功能减退症中的死亡率、心血管事件及危险因素。
Growth Horm IGF Res. 1998 Feb;8 Suppl A:69-76. doi: 10.1016/s1096-6374(98)80013-0.
9
10

引用本文的文献

1
Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.韩国垂体腺瘤的发病率、死亡率和心血管疾病:一项全国基于人群的研究。
Pituitary. 2021 Feb;24(1):38-47. doi: 10.1007/s11102-020-01084-6. Epub 2020 Sep 19.
2
Radiotherapy for craniopharyngioma.颅咽管瘤的放射治疗。
Pituitary. 2013 Mar;16(1):26-33. doi: 10.1007/s11102-012-0429-1.
3
Radiotherapy for non-functioning pituitary tumors--when and under what circumstances?

本文引用的文献

1
Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.垂体腺瘤神经外科治疗后垂体功能减退的恢复
J Clin Endocrinol Metab. 1999 Oct;84(10):3696-700. doi: 10.1210/jcem.84.10.6019.
2
The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.十年重组人生长激素(GH)对成年生长激素缺乏患者的影响。
J Clin Endocrinol Metab. 1999 Aug;84(8):2596-602. doi: 10.1210/jcem.84.8.5916.
3
Life expectancy following surgery for pituitary tumours.垂体瘤手术后的预期寿命。
Pituitary. 2003 Sep;6(2):103-8. doi: 10.1023/b:pitu.0000004801.95086.e2.
Clin Endocrinol (Oxf). 1999 Mar;50(3):315-9. doi: 10.1046/j.1365-2265.1999.00650.x.
4
Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.生长激素(GH)治疗可逆转生长激素缺乏的成年人早期动脉粥样硬化变化。
J Clin Endocrinol Metab. 1999 Feb;84(2):453-7. doi: 10.1210/jcem.84.2.5456.
5
Emerging epidemic of cardiovascular disease in developing countries.发展中国家心血管疾病的新流行趋势。
Circulation. 1998 Feb 17;97(6):596-601. doi: 10.1161/01.cir.97.6.596.
6
The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe.欧洲心血管疾病死亡率负担。欧洲心脏病学会欧洲心血管疾病死亡率和发病率统计工作组。
Eur Heart J. 1997 Aug;18(8):1231-48.
7
Increased cerebrovascular mortality in patients with hypopituitarism.垂体功能减退患者脑血管死亡率增加。
Clin Endocrinol (Oxf). 1997 Jan;46(1):75-81. doi: 10.1046/j.1365-2265.1997.d01-1749.x.
8
Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.成年生长激素(GH)缺乏患者在儿童期发病和成年期发病的患者中,在接受人生长激素治疗之前和期间表现出异质性。成年生长激素缺乏研究组。
J Clin Endocrinol Metab. 1997 Jan;82(1):82-8. doi: 10.1210/jcem.82.1.3643.
9
Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.生长激素缺乏的成年人长期接受生长激素治疗可降低纤溶酶原激活物抑制剂-1和组织纤溶酶原激活物水平。
Thromb Haemost. 1996 Sep;76(3):422-8.
10
The effect of hypopituitarism on life expectancy.垂体功能减退对预期寿命的影响。
J Clin Endocrinol Metab. 1996 Mar;81(3):1169-72. doi: 10.1210/jcem.81.3.8772595.